Tag - Daktari Diagnostics

Gates is Still Gunning for HIV. Here’s the Latest

Ziad2022-11-25T14:05:41-05:00Gates has been backing HIV self-testing and rapid diagnostics projects since around 2010, when it invested $600,000 in Daktari Diagnostics, a company focused on “delivering critical diagnostic test results.” In 2015, Daktari rolled out its portable point-of-care device that measures CD4 cell counts. CD4s are white blood cells that fight infection and are defined as “antigen[s] found on helper T cells.” The following year, in 2011, Gates awarded PATH a $1.1 million grant to “develop a target product profile for...

Museum of Science showcases local innovation in new exhibit

Ziad2022-11-25T14:05:41-05:00One of the most important inventions is the Daktari CD4 System, a portable device designed to improve treatment for people with AIDS and HIV by allowing them to quickly measure their CD4 cells, white blood cells that fight infection. After pricking their finger, people load a cartridge into a machine that looks like a cassette player and get results in 15 minutes. Read more >>

Daktari Achieves Milestone in Its Merck HCV Collaboration

Ziad2022-11-25T14:05:54-05:00Daktari Diagnostics, a company focused on making “Anywhere. Care.™” a reality with its portable and ultrasensitive immunoassay-based CarePlatform™, today announced that it has reached a milestone in its global collaboration with Merck, known as MSD outside the United States and Canada, for the development of Daktari’s rapid point-of-care (POC) hepatitis C virus (HCV) core antigen confirmatory test system. Read more >>

Daktari Announces Formation of Scientific Advisory Board

Ziad2022-11-25T14:06:05-05:00Daktari Diagnostics, a company focused on making “Anywhere. Care.™” a reality with its portable and ultrasensitive immunoassay-based CarePlatform™, today announced the formation of its Scientific Advisory Board (SAB) comprised of global leaders in the diagnostic and biotechnology industries. The SAB will work closely with Daktari’s management team to advance the development of the Company’s rapid and clinically relevant point-of-care (POC) diagnostic solutions. Read more >>